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Polymerase chain reaction screening
for fungemia and/or invasive fungal infections
in patients with hematologic malignancies
Abstract Introduction: Invasive
fungal infections (IFIs) are a life-
threatening complication in patients
with hematologic malignancies,
mainly in acute leukemia patients,
following chemotherapy. IFI inci-
dence is increasing, and associated
mortality remains high due to unreli-
able diagnosis. Antifungal drugs are
often limited by inadequate antimi-
crobial spectrum and side effects.
Thus, the detection of circulating
fungal DNA has been advocated as a
rapid, more sensitive diagnostic tool.
Patients and methods: Between June
01 and January 03, weekly blood
samples (1,311) were screened from
193 patients undergoing intensive
myelosuppressive or immunosup-
pressive therapy. IFI cases were
classified according to European
Organization for Research and Treat-
ment of Cancer/Mycoses Study
Group criteria. Fungal DNA was
extracted from whole blood and
amplified using polymerase chain
reaction (PCR) published primers that
bind to the conserved regions of the
fungal 18S rRNA gene sequence. In
our study, two or more consecutive
positive samples were always asso-
ciated with fungal disease. Results:
PCR screening predicted the devel-
opment of IFI to be 17 days (median).
This test had a specificity of 91.1%
and a sensitivity of 75%. IFI inci-
dence was 7.8%. Discussion: There-
fore, our results confirm the potential
usefulness of PCR serial screening
and the clinical applicability in
everyday routine. PCR screening
offers a noninvasive repeatable aid to
the diagnosis of IFI.
Keywords Neutropenia . Fungal
infections . PCR screening
Introduction
In patients with hematologic malignancies, opportunistic
mycosis often develops into severe invasive fungal infec-
tion (IFI), which is a life-threatening complication. Uni-
form experience indicates that this is most frequent in
patients with acute leukemia, partly due to the introduction
of more intensive combination of chemotherapeutic regi-
mens. These cause more prolonged myelosuppression that
results in delays in the recovery of the immune system that
will likely end in fatal infections [1, 2]. Furthermore, these
chemotherapy regimens cause mucositis, permitting the
establishment of local fungal infections and subsequent
hematogenous dissemination. These regimens are deliv-
ered through central venous catheters which contribute to
the breakdown of normal anatomic barriers, thereby in-
creasing the chance of nosocomial infections [3]. The con-
comitant use of broad-spectrum antibiotic drugs will
suppress the endogenous bacterial flora, permitting fungi
overgrowth. Hence, it is not surprising that a gradual
increase in IFI incidence has been observed [4]. It is
difficult, however, to obtain an accurate estimate of the
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frequency of fungal infections in patients with cancer [5].
Most reports do not provide sufficient information re-
garding the nature of the underlying disease, many focus on
a single fungus, and the frequency of IFI varies con-
siderably between different institutions [6]. To complicate
even more the issue, some fungal infections are only
discovered at the autopsy [7].
It has become clinical standard practice to administer
antifungal therapy empirically to febrile patients [8],
making it difficult to determine the proportion of respond-
ing patients who were actually infected with fungi. In
general, the severity of IFI has led to the adoption of an
aggressive approach by most clinical centers, since time is
a critical factor in determining successful outcome. How-
ever, empirical therapy has risks. Most antifungal drugs
have side effects, so early and accurate diagnosis of these
infections is important to decrease the use of unnecessary
toxic agents [9].
Guidelines have been drawn as to the use of diagnostic
techniques to determine more accurately who will need
antifungal therapy. These include radiological investigation
with computerized tomography scans, invasive procedures
for histological examinations and mycological techniques
of culture, and finally, serology tests [10, 11]. However, the
performance of invasive procedures is often precluded by
profound cytopenias. The detection of fungi by standard
culture is often delayed because of slow or absent growth
of fungal isolates. Examination of bronchoalveolar lavage
may be positive in up to 60% in cases of aspergillosis with
diffuse disease but has limited value for either focal disease
or Candida pneumonia [12].
Another diagnostic approach is the use of fungal man-
nans or galactomannans [13, 14]. Several techniques, like
enzyme immunoassays, radioimmunoassay, and latex par-
ticle agglutination tests, have been evaluated for the de-
tection of galactomannan, but their routine use has been
difficult due to a low detection limit, to cross-reactivity
with exoantigens from bacteria, food mannans, antibiotics,
or cytotoxic agents such as cyclophosphamide [15, 16].
These fungal antigens may even be rapidly removed from
circulation by the formation of immune complexes and by
receptor-mediated endocytosis by Kupffer cells in the
liver, thereby limiting the sensitivity of these diagnostic
approaches [17].
The detection of circulating fungal DNA has been con-
sidered as a promising tool, more rapid and more sensitive
than serologic techniques [13, 18]. Polymerase chain re-
action (PCR) methods are being developed, which may
permit early detection by analyzing several different types
of samples. Despite the variety of strategies being devel-
oped, some have shown limited applicability for routine
use in a clinical setting, and so far, most studies were
performed in limited numbers of patients [18, 19].
In the present report, a large prospective study was un-
dertaken in a single center to evaluate the value of PCR as a
routine screening procedure in patients with hematologic




Between October 2000 and January 2003, 193 patients
were admitted to wards equipped with high-efficacy par-
ticulate air filters for intensive myelosuppressive or im-
munosuppressive therapy. These patients (Table 1) were
admitted to our institution, and most patients (141) were
submitted to the first induction therapy with idarubicin (12
mg/m2, days 1–3) plus AraC (100 mg/m2, days 1–7) for all
acute myeloid leukemia except promyelocytic acute leu-
kemia patients who are treated with trans-retinoic acid plus
idarubicin (12 g/m2) or for acute lymphoblastic leukemia
patients who were treated with alternate cycles of high-
dose cyclophosphamide, doxorubicin, and AraC and cycles
of high-dose methrotexate plus AraC. Consolidation ther-
apy for acute myeloid leukemia was given to 127 patients
[mitoxantrone (10 mg/m2, days 2–6) plus high-dose AraC
(3 g/m2, days 1, 3, and 5)], 27 patients were on high-dose
chemotherapy for autologous peripheral blood progenitor
cell transplantation, and finally, 123 patients were on
further regimens of chemotherapy [=3 cycles with etopo-
side (200 mg, days 8–10), mitoxantrone (12 mg, days 1–3),
and AraC (500 mg/m2, days 1–3 and 8–10)]. Severe
aplastic anemia patients treated with anti-thymocytic sera
and some lymphoma patients treated with ESHAP (etopo-
side, cis-platinum, doxorubicin, and methylprednisolone)
were included in the induction therapy group for analysis
simplification.
Fungal infection was classified according to the Euro-
pean Organization for Research and Treatment of Cancer
Table 1 Patient characteristics
No. Patients 193
No. of neutropenic episodes 418
Median age/range (years) 50/16–77
Male/female 113/80
Median time to neutrophil recovered (days) 26
WBC nadir count 300/ìl
Diagnosis
Acute myeloid leukemia 119
Acute lymphoblastic leukemia 26
Severe aplastic anemia 8
Non-Hodgkin’s and Hodgkin’s lymphoma 40
Treatment episodes
Induction chemotherapy (1st) 141
Consolidation chemotherapy 127
Autologous PBSCT 27
Chemotherapy (relapse patients) 123
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(EORTC)/Invasive Fungal Infections Cooperative Group
and Mycoses Study Group (MSG) international consensus
criteria [11].
Two peripheral blood samples were taken for microbi-
ology analysis prior to empiric antibiotic institution and
whenever a drug modification was necessary. This oc-
curred when unresponsive fever was present or clinical
deterioration was observed. Secondary prophylaxis with
antifungal therapy was given to patients with a previous
episode of proven or probable invasive aspergillosis (IA).
Results from PCR analysis were confidential during the
first year of the study and were disclosed after the said
period, but clinical workup for disease proceeded as usual.
Study design and PCR assay
Consecutive blood samples were collected at entry, then
weekly until death or hospital discharge, using 5-ml vacu-
tainer tubes with EDTA to minimize chances of environ-
mental contamination. The vacutainer’s rubber stopper was
carefully removed, and whole blood was aseptically trans-
ferred, using a disposable pipette with a filtered tip, into a
12-ml centrifuge tube. Erythrocytes were lysed with 10 ml
of erythrocyte lysis buffer (10 mM Tris pH 7.6, 5 mM
MgCl2, 10 mM NaCl) by incubation for 10 min at 37°C
and then separated by centrifugation (5 min, 1,800 rpm).
The procedure was repeated twice. The pellet was then
lysed by incubation (water bath 65°C, 45 min) with a
leukocyte lysis buffer (10 mM Tris pH 7.6, 10 mM EDTA
pH 8.0, 50 mM NaCl, 0.2% sodium dodecyl sulfate,
200 μg/ml proteinase K), then separated by centrifuga-
tion (10 min, 4,000 rpm) [20]. NaOH (1 ml of 50 mM)
was added, followed by incubation for 10 min at 95°C.
Then, 1 ml of 1 mM Tris pH 7.0 was added for neutral-
ization. Fungal cell walls were lysed by adding a digestion
mixture of 50 mM Tris pH 7.5, 1 mM EDTA, beta-2-
mercaptoethanol 28 mM, 300 μg/ml lyticase solution
(Sigma) [20]. Incubation (room temperature, 45 min) was
followed by centrifugation for 10 min at 5,000 rpm.
Supernatant was carefully removed, the pellet was re-
suspended into DNAzol BD reagent (Gibco BRL), and
extraction was performed according to manufacturer’s
recommendations.
Fungal DNA (5 μl) was amplified in a 50-μl reaction
volume, with 1.25 U Taq polymerase (Gibco BRL) and
with panfungal PCR published primers [21] that bind to the
conserved regions of the fungal 18S rRNA gene sequence.
PCR-amplified products of 197 bp were obtained by using
the forward 5′-ATTGGAGGGCAAGTCTGGTG-3′ and
the reverse 5′-CCGATCCCTAGTCGGCATAG-3′ primers
(synthesized by Gibco BRL). Amplification started with a
denaturation step at 94°C for 5 min, 35 cycles of 94°C for
45 s, 62°C for 1 min and 30 s, 72°C for 2 min, ending in a
final elongation step at 72°C for 10 min. Established PCR
negative and positive control samples were used in every
assay. PCR final products were electrophoresed through a
1.8% agarose gel stained with ethidium bromide and UV
photographed (Kodak 120 camera system).
This study also allows for indirect characterization of
fungal species. Using the primers described above, occa-
sionally, a 492- and 503-bp PCR-amplified products were
obtained due to the highly variable internal transcribed
spacer (ITS) regions, common in the general fungus ge-
netic code. Looking through the fungal nucleotide pub-
lished sequences in the GenBank database (accession
numbers AJ005123 and AF320009), we found that these
could match Candida albicans and Ajellomyces capsulatus
(Histoplasma capsulatus), respectively.
Statistical analysis
The calculation of sensitivity of the PCR assay was based
on the episodes with proven IA, probable IA, candidemia,
and chronic disseminated candidiasis (CDC). For the
calculation of specificity, episodes without criteria for IFI
according to the EORTC/MSG 2002 international con-
sensus classification [11] were considered true negative
episodes.
Results
A total of 1,311 whole blood samples from 418 neutropenic
episodes (mean 3.14 samples/episode, mean 6.8 samples
per patient, range 1–9) were analyzed by PCR: 153 epi-
sodes were classified as fever with microbiological doc-
umentation (143 with bacteremia; 2, viral infection; 1,
histoplasmosis; 2, Pneumocystis carinii; 2, tuberculosis;
and 3, candidemias: 2 C. albicans and 1 Candida krusei),
75 episodes were characterized as fever of unknown origin,
39 episodes without fever, and 151 episodes had fever with
clinical documentation among which, 60 were pneumo-
nias. Details of 51 patients suspected of having pulmonary
IA are shown in Table 2, paired with PCR results and the
number of samples tested. The remaining correspondence
of sampling and PCR positive assays are in Table 3. In the
group characterized by fever with clinical documentation, a
correspondence between some episodes and patients was
observed: four episodes of CDC (corresponding to four
Table 2 Blood samples tested by PCR in different patients
EORTC/MSG
criteria IA
No. of patients PCR positive
once (twice)
Tested samples
Proven 1 1 (0) 1
Probable 11 11 (4) 61
Possible 19 5 (1) 111
Unlikely 20 2 (0) 83
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patients, one patient had a candidemia and, during another
neutropenic episode, developed a CDC).
On the whole 1,311 samples, 76 samples were PCR
positive. Only 15 patients fulfill all the requirements,
according to the EORTC/MSG criteria, for having a deep
fungal disease (Table 4). The IFI incidence among the 193
patients is 7.8%. Two or more consecutive or intermittently
positive PCR samples for the same patient were observed
for several patients, and, in these cases, the positivity was
always associated with fungal disease. Screening predicted
the appearance of IFI to be 17 days (median). In one case, a
patient with relapsed acute lymphoblastic leukemia had
intermittently positive PCR samples, but a fungal infection
was not found. She was discharged and readmitted one
week later with fever, PCR positive tests, and a candide-
mia. From the first PCR positive test until microbiological
determination, a 4-week period elapsed.
The evaluation of the PCR screening impact is shown in
Table 4. We found 7.2% of false positives and 2.5% of false
negatives. In our study, a specificity of 91.1% and a
sensitivity of 75% were obtained.
Discussion
In the present study, we found an IFI incidence of 7.8% in
patients with hematologic malignancies. The criteria used
in this study were based on the definitions proposed by the
EORTC/MSG consensus [11], which may lead to an
underestimate of the incidence of IFI infections. However,
candidemia rates of 6.3% [22] and aspergillosis rates of 6%
[23] were found in previous reports at our institution, and
recently, similar rates have been published [24]. A
substantial number of studies have been focusing on the
rising of IFI incidence in the last decades [3, 4, 11, 18];
there is, however, a considerable variation in the range of
organisms isolated in different hospitals, and unfortunately,
it is difficult to have precise numbers [3, 5]. Probably, on
the whole, IFI incidence has stabilized; between 1950 and
1980, some studies reported a variable incidence of 20 to
60% among patients with acute leukemia [7, 25].
This report describes a panfungal PCR assay based on
a lysis centrifugation method, which allows for repeated
testing on multiple occasions. Although the procedure is
easy to perform, the sensitivity of the assay was quite low
(75%) compared to some published data [19, 26]. However,
in these reports, only IA was screened. Our results are in
accordance with others [18, 21], but specimen preparation
can have a significant impact on the sensitivity. DNA iso-
lation from some fungal organisms is difficult due to cell
walls that are not readily susceptible to lysis, although the
presence of the usual smear of DNA on the agarose gel
permits differentiation from other causes of false negative
tests. Other reasons for a false negative test are the presence
of potential inhibitors of the fungus PCR reaction and/or the
lower amount of fungal DNA in the sample [20]. Antifun-
gal treatment and hepatic clearance may cause intermittent
clearing of the organism from the bloodstream [17]. PCR
negativity may also be due to the half-life of circulating
DNA [27]. The use of universal probes designed to detect a
single-copy gene has low sensitivity when compared to
specific probes targeting multicopy genes [28], but these
are time consuming and not applicable in everyday rou-
tine, considering the large number of potentially pathogen-
ic fungi. Furthermore, the chosen sequences in our study
have highly variable ITS regions which allow for exploi-
tation for species identification and further confirmation
by sequencing analysis. On the other hand, since fungi are
ubiquitous in the environment, panfungal PCR methods
are more likely to yield contaminated products, while the
use of specific probes will reduce this possibility [13,
20]. Sensitivity will probably improve if amplification is
achieved by nested PCR [13, 19], although some reports
have showed similar sensitivity results [26] to ours. Sen-
sitivity will also improve by using real-time PCR [26].
This latter method reduces the risk of contamination and
permits fungal quantification. This will answer some
clinical questions as the correlation between the disap-
pearance of fungal DNA from the blood and treatment
success; in fact, it may even be used to tailor treatment
duration. Recently, a quantitative PCR assay with the
Table 3 PCR tests and
classification episodes
Classification No. of episodes PCR positive tests Tested samples
Fever (unknown origin) 75 10 (5/1 patient) 210
Episodes without fever 39 1 80
Clinical documentation fever 151 22 602
(4 CDC) (6) (25)
Microbiological documentation fever 153 24 419
(3 Candidem) (4) (5)
(1 Histoplasm) (8) (30)
Table 4 Data comparing PCR tests and final diagnosis according to
EORTC/MSG
PCR With IFI Without IFI Total patients
Positive 15 14 29
Negative 5 159 164
Total patients 20 173 193
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LightCycler detection system was described as promising
[26].
The specificity in our study was 91.1%, which is quite
high and in concordance with other studies [18, 19, 26].
The discrepancy encountered in our study regarding sen-
sitivity and specificity may be explained by a bias intro-
duced by a higher sampling frequency in patients with
fever and clinical documentation, namely, possible IA and
unlikely IA compared to proven IFI (Tables 2 and 3). False
positive results from 8 to 38% have been observed [13, 27].
Some patients were intermittently positive in our study,
which may be related to exogenous contamination. There-
fore, any positive result must be confirmed with a second
positive result taken on a different occasion. Furthermore,
fungemia may be intermittent due to hepatic clearance [17].
The present study describes a universal fungal detection
protocol that is simple, rapid, repeatable, and noninvasive
and has clinical applicability in everyday routine. As a
screening method, it is feasible and can be applied to all
sorts of samples [whole blood as demonstrated but also to
British antilewisite and histology material (unpublished
data)]. It allows for early diagnosis provided regular serial
sampling is obtained. It is cost-effective when compared to
the economical impact of administering antifungal drugs to
all patients. Sensitivity has to be improved by introducing
better amplification methods as discussed. Our results
suggest that molecular biology methods are more sensitive
than the standard sera testing by immunological/enzyme-
linked immunosorbent assay methods [13, 27]. The advan-
tage of a future commercial PCR diagnostic kit would be
to standardize methodology between centers and reduce
the possibility of contamination. Although PCR-based tests
cannot replace other diagnostic procedures, they represent
a valuable aid. A high index of suspicion and careful
clinical and radiological examinations are requisites to
early identification of IFI patients and aggressive treat-
ment steps, which are mandatory for outcome success in
patients with hematologic malignancies. However, PCR
may lead to preemptive antifungal therapy, may monitor
therapeutic response, may detect drug resistant species,
and will slowly modify the severity of fungal infections.
We also suggest a multicenter trial to validate our results,
although we favor a more sensitive approach as a quan-
titative PCR method.
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